Transcending conventional therapies: The role of biologic and other novel therapies

Inflammatory Bowel Diseases

Volumn 7, Issue SUPPL. 1, 2001, Pages

  Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antiadhesion molecules; Crohn's disease; Etanercept; Inflammatory bowel disease; Infliximab; Integrin alpha; Interleukin; Mycophenolate; Tacrolimus; Thalidomide; Tumor necrosis factor alpha

Indexed keywords

ALPHA4 INTEGRIN; BIOLOGICAL RESPONSE MODIFIER; CELL ADHESION MOLECULE; CYTOKINE; DRUG DERIVATIVE; GASTROINTESTINAL AGENT; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INOSINATE DEHYDROGENASE; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT PROTEIN; TACROLIMUS; THALIDOMIDE; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

CLINICAL TRIAL; CROHN DISEASE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IMMUNOLOGY; PATHOPHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; BIOLOGICAL RESPONSE MODIFIERS; CELL ADHESION MOLECULES; CLINICAL TRIALS; CROHN DISEASE; CYTOKINES; DRUGS, INVESTIGATIONAL; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; INTEGRIN ALPHA4; MYCOPHENOLIC ACID; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; TACROLIMUS; THALIDOMIDE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035345237     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1002/ibd.3780070504     Document Type: Article

References (5)

1. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000;118:568-582.
2. Van Deventer SJH. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-8.
3. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995;7:251-9.
4. Siegel SA, Shealy DJ, Nakada MT, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transsenic mice from cachexia and TNF lethality in vivo. Cytokine 1995;7:15-25.
5. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.